Re-engineering of TNFα-NF-κB signalling dynamics in cancer cells using pathogenic E. coli effectors

Re-engineering NF-κB signalling towards enhancing beneficial outcomes such as tumour cell elimination, while minimising inflammatory damage, is a potential therapeutic avenue. In this study, we explored the ability of bacterial effectors injected into host cells by the type III secretion system to regulate NF-κB translocation dynamics. We used the enteropathogenic Escherichia coli effectors Tir (NF-κB activator), NleC (NF-κB protease) and NleE (TAB2/3 methyltransferase), to manipulate NF-κB translocation and cancer cell survival. We discovered that while these effectors have either limited or no cytotoxicity alone, they greatly enhanced caspase-8-dependent pancreatic cancer cell death in the presence of TNFα. Single cell analysis revealed that the sub-population of cells showing high NF-κB activation is less susceptible to cell death caused by NleC or NleE but instead is more susceptible to Tir. A combination of Tir, NleE and TNFα eliminated 95% cancer cells with limited NF-κB activation, potentially due to NleE-dependent blockage of the immediate pro-survival NF-κB activation without inhibiting Tir’s long-term NF-κB activation that promotes cell death. This work demonstrates that effector combinations could be used to re-engineer stress responses towards favourable outcomes.

[1]  M. Rogg,et al.  Proteome alterations during clonal isolation of established human pancreatic cancer cell lines , 2022, Cellular and Molecular Life Sciences.

[2]  Yohei Kondo,et al.  LIM Tracker: a software package for cell tracking and analysis with advanced interactivity , 2022, Scientific Reports.

[3]  C. Bakal,et al.  Actin networks modulate heterogenous NF-κB dynamics in response to TNFα , 2022, bioRxiv.

[4]  J. Choudhary,et al.  EPEC‐induced activation of the Ca2+ transporter TRPV2 leads to pyroptotic cell death , 2021, Molecular microbiology.

[5]  Jie Zhou,et al.  Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis , 2021, Frontiers in Pharmacology.

[6]  J. Garssen,et al.  Chemotherapy: a double-edged sword in cancer treatment , 2021, Cancer Immunology, Immunotherapy.

[7]  S. Cook,et al.  Inhibitory feedback control of NF-κB signalling in health and disease , 2021, The Biochemical journal.

[8]  Nichollas E. Scott,et al.  NleB2 from enteropathogenic Escherichia coli is a novel arginine-glucose transferase effector , 2021, PLoS pathogens.

[9]  Prachi Mishra,et al.  The Role of Tumor Necrosis Factor in Manipulating the Immunological Response of Tumor Microenvironment , 2021, Frontiers in Immunology.

[10]  C. Bakal,et al.  Clustering of Tir during enteropathogenic E. coli infection triggers calcium influx–dependent pyroptosis in intestinal epithelial cells , 2020, PLoS biology.

[11]  V. Tergaonkar,et al.  Small Molecule NF-κB Pathway Inhibitors in Clinic , 2020, International journal of molecular sciences.

[12]  Kaiwen W. Chen,et al.  Human GBP1 binds LPS to initiate assembly of a caspase-4 activating platform on cytosolic bacteria , 2020, Nature Communications.

[13]  L. Collinson,et al.  Human GBP1 Differentially Targets Salmonella and Toxoplasma to License Recognition of Microbial Ligands and Caspase-Mediated Death , 2019, Cell reports.

[14]  N. Meyer,et al.  The TNF Paradox in Cancer Progression and Immunotherapy , 2019, Front. Immunol..

[15]  V. Hornung,et al.  Human GBP1 is a microbe‐specific gatekeeper of macrophage apoptosis and pyroptosis , 2019, The EMBO journal.

[16]  M. Plebani,et al.  Inflammation and Pancreatic Cancer: Focus on Metabolism, Cytokines, and Immunity , 2019, International journal of molecular sciences.

[17]  Hongkai Ji,et al.  Transcriptional outcomes and kinetic patterning of gene expression in response to NF-κB activation , 2018, PLoS biology.

[18]  D. Munn,et al.  Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-α-Dependent Intensification of Oxidative Stress and Tumor Cell Death. , 2018, Cell metabolism.

[19]  K. Brown,et al.  Tumor immune evasion arises through loss of TNF sensitivity , 2018, Science Immunology.

[20]  A. Agresti,et al.  NF-κB, the Importance of Being Dynamic: Role and Insights in Cancer , 2018, Biomedicines.

[21]  Masahiro Yamamoto,et al.  LPS targets host guanylate‐binding proteins to the bacterial outer membrane for non‐canonical inflammasome activation , 2018, The EMBO journal.

[22]  R. Hoffman,et al.  Bacterial Therapy of Cancer: Promises, Limitations, and Insights for Future Directions , 2018, Front. Microbiol..

[23]  L. A. Fernández,et al.  Attaching and effacing (A/E) lesion formation by enteropathogenic E. coli on human intestinal mucosa is dependent on non-LEE effectors , 2017, PLoS pathogens.

[24]  G. Schmidt,et al.  Bacterial Toxins for Cancer Therapy , 2017, Toxins.

[25]  Shao-Cong Sun,et al.  NF-κB signaling in inflammation , 2017, Signal Transduction and Targeted Therapy.

[26]  M. Schmidt,et al.  Cell-Penetrating Bacterial Effector Proteins: Better Tools than Targets. , 2017, Trends in biotechnology.

[27]  Laura F. Dagley,et al.  EspL is a bacterial cysteine protease effector that cleaves RHIM proteins to block necroptosis and inflammation , 2017, Nature Microbiology.

[28]  Zheng Zhang,et al.  Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma , 2016, Oncotarget.

[29]  M. Bianchi,et al.  NF-κB oscillations translate into functionally related patterns of gene expression , 2016, eLife.

[30]  W. Thabet,et al.  Enteropathogenic Escherichia coli (EPEC): Does it have a role in colorectal tumourigenesis? A Prospective Cohort Study. , 2015, International journal of surgery.

[31]  Hai-Jie Yang,et al.  NF-κB Regulates Caspase-4 Expression and Sensitizes Neuroblastoma Cells to Fas-Induced Apoptosis , 2015, PloS one.

[32]  Dinesh Vyas,et al.  Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis , 2014, OncoTargets and therapy.

[33]  Masahiro Yamamoto,et al.  Guanylate binding proteins promote caspase-11–dependent pyroptosis in response to cytoplasmic LPS , 2014, Proceedings of the National Academy of Sciences.

[34]  She Chen,et al.  Pathogen blocks host death receptor signalling by arginine GlcNAcylation of death domains , 2013, Nature.

[35]  T. Bekaii-Saab,et al.  Disrupting Cytokine Signaling in Pancreatic Cancer: A Phase I/II Study of Etanercept in Combination With Gemcitabine in Patients With Advanced Disease , 2013, Pancreas.

[36]  Hao Wang,et al.  Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Lee,et al.  NF-κB Directly Regulates Fas Transcription to Modulate Fas-mediated Apoptosis and Tumor Suppression* , 2012, The Journal of Biological Chemistry.

[38]  D. Vaux,et al.  IAPs limit activation of RIP kinases by TNF receptor 1 during development , 2012, The EMBO journal.

[39]  J. Chen,et al.  Cysteine methylation disrupts ubiquitin-chain sensing in NF-κB activation , 2011, Nature.

[40]  R. Zarivach,et al.  Metalloprotease type III effectors that specifically cleave JNK and NF‐κB , 2011, The EMBO journal.

[41]  Tetsuya Hayashi,et al.  NleC, a Type III Secretion Protease, Compromises NF-κB Activation by Targeting p65/RelA , 2010, PLoS pathogens.

[42]  J. Turner,et al.  Enteropathogenic E. coli non‐LEE encoded effectors NleH1 and NleH2 attenuate NF‐κB activation , 2010, Molecular microbiology.

[43]  J. Teissié,et al.  Caspase-10-Dependent Cell Death in Fas/CD95 Signalling Is Not Abrogated by Caspase Inhibitor zVAD-fmk , 2010, PloS one.

[44]  J. Whisstock,et al.  The Type III Effectors NleE and NleB from Enteropathogenic E. coli and OspZ from Shigella Block Nuclear Translocation of NF-κB p65 , 2010, PLoS pathogens.

[45]  T. Meyer,et al.  The Type III Secretion Effector NleE Inhibits NF-κB Activation , 2010, PLoS pathogens.

[46]  B. Finlay,et al.  Bacterial Effector Binding to Ribosomal Protein S3 Subverts NF-κB Function , 2009, PLoS pathogens.

[47]  F. Balkwill Tumour necrosis factor and cancer , 2009, Nature Reviews Cancer.

[48]  Xiaodong Wang,et al.  TNF-α Induces Two Distinct Caspase-8 Activation Pathways , 2008, Cell.

[49]  H. Wajant,et al.  Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. , 2008, Cancer research.

[50]  W. Weichert,et al.  High expression of RelA/p65 is associated with activation of nuclear factor-κB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis , 2007, British Journal of Cancer.

[51]  M. Nagarkatti,et al.  Role of Dioxin Response Element and Nuclear Factor-κB Motifs in 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Mediated Regulation of Fas and Fas Ligand Expression , 2006, Molecular Pharmacology.

[52]  N. Perkins,et al.  Good cop, bad cop: the different faces of NF-κB , 2006, Cell Death and Differentiation.

[53]  Allan R Brasier,et al.  A TNF-induced gene expression program under oscillatory NF-κB control , 2005, BMC Genomics.

[54]  P. Barker,et al.  Nuclear factor-kappaB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-kappaB-dependent transcription in cancer cells. , 2005, Cancer research.

[55]  James R. Johnson,et al.  Oscillations in NF-κB Signaling Control the Dynamics of Gene Expression , 2004, Science.

[56]  N. Perkins,et al.  Active Repression of Antiapoptotic Gene Expression by RelA(p65) NF-κB , 2004 .

[57]  J. Tschopp,et al.  Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes , 2003, Cell.

[58]  J. Nougayrède,et al.  Adhesion of enteropathogenic Escherichia coli to host cells , 2003, Cellular microbiology.

[59]  D. Trisciuoglio,et al.  relA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells , 2001, British Journal of Cancer.

[60]  H. Chun,et al.  Caspase-10 is an initiator caspase in death receptor signaling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[61]  T. Pawson,et al.  Enteropathogenic E. coli Tir binds Nck to initiate actin pedestal formation in host cells , 2001, Nature Cell Biology.

[62]  J. Tschopp,et al.  NF-κB Signals Induce the Expression of c-FLIP , 2001, Molecular and Cellular Biology.

[63]  Peter Scheurich,et al.  NF-κB Inducers Upregulate cFLIP, a Cycloheximide-Sensitive Inhibitor of Death Receptor Signaling , 2001, Molecular and Cellular Biology.

[64]  Ye Zheng,et al.  NF-κB RelA (p65) Is Essential for TNF-α-Induced Fas Expression but Dispensable for Both TCR-Induced Expression and Activation-Induced Cell Death1 , 2001, The Journal of Immunology.

[65]  K. Vousden,et al.  Role of NF-κB in p53-mediated programmed cell death , 2000, Nature.

[66]  Marty W. Mayo,et al.  NF-κB Induces Expression of the Bcl-2 Homologue A1/Bfl-1 To Preferentially Suppress Chemotherapy-Induced Apoptosis , 1999, Molecular and Cellular Biology.

[67]  Peter Scheurich,et al.  The Human Tumor Necrosis Factor (TNF) Receptor-associated Factor 1 Gene (TRAF1) Is Up-regulated by Cytokines of the TNF Ligand Family and Modulates TNF-induced Activation of NF-κB and c-Jun N-terminal Kinase* , 1999, The Journal of Biological Chemistry.

[68]  Claus Scheidereit,et al.  NF-κB Function in Growth Control: Regulation of Cyclin D1 Expression and G0/G1-to-S-Phase Transition , 1999, Molecular and Cellular Biology.

[69]  C. Y. Wang,et al.  NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. , 1998, Science.

[70]  Christian Stehlik,et al.  Nuclear Factor (NF)-κB–regulated X-chromosome–linked iap Gene Expression Protects Endothelial Cells from Tumor Necrosis Factor α–induced Apoptosis , 1998, The Journal of experimental medicine.

[71]  B. Finlay,et al.  Enteropathogenic E. coli (EPEC) Transfers Its Receptor for Intimate Adherence into Mammalian Cells , 1997, Cell.

[72]  Hong-Bing Shu,et al.  TRADD–TRAF2 and TRADD–FADD Interactions Define Two Distinct TNF Receptor 1 Signal Transduction Pathways , 1996, Cell.

[73]  Daniel S Waterman,et al.  ESCHERICHIA COLI STRAINS THAT CAUSE DIARRHŒA BUT DO NOT PRODUCE HEAT-LABILE OR HEAT-STABLE ENTEROTOXINS AND ARE NON-INVASIVE , 1978, The Lancet.

[74]  Abigail Clements,et al.  Modulation of Host Cell Processes by T3SS Effectors. , 2018, Current topics in microbiology and immunology.